Nordicus Partners Corporation (NORD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -4 | -4 | ||||||
| Net profit | $m | -0 | -0 | -8,465 | -0 | -3 | 0 | - | - |
| EPS reported | $ | -0.22 | -0.22 | ||||||
| Operating cashflow per share | $ | -0.24 | -0.25 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.24 | -0.25 | ||||||
| Free cash flow | $m | -4 | -5 | ||||||
| Net debt | $m | -0 | -0 | ||||||
| Book value equity | $m | 64 | 64 | ||||||
| Book value per share | $ | 3.55 | 3.55 | ||||||
| Number of shares | m | 18.12 | 18.12 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.68 | 0.68 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -10.07 | -9.67 | ||||||
| EV/EBITDA LTM | x | -10.00 | -9.73 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | +0.00% | -5.39% | ||||||
| FCF Yield | % | -9.93% | -10.35% | ||||||
| Quality | |||||||||
| ROE | % | +0.00% | -6.20% | ||||||
| ROIC | % | +0.00% | -5.86% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | -100.00% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.00 | 0.00 | ||||||
| EBIT/Net interest | x | 6,808.41 | 16,562.69 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.00 | -0.00 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free